Contract

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

Exhibit 10.47

 

 

May 16, 2005

 

▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇

▇▇▇▇▇▇-▇▇▇▇ Pharmaceuticals, Inc.

▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇

▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇

 

Dear ▇▇. ▇▇▇▇▇▇:

 

The purpose of this letter agreement (Amendment 6) is to amend further the contract dated June 18, 2003. By signing below, the undersigned parties hereby agree to amend [ * ] of Exhibit B and replace them with [ * ] as reflected below:

 

[ * ]

 

		Total		$	1,700,000

 

[ * ]

 

Page 1

---

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.
By:		/s/ ▇. ▇▇▇▇▇						/s/ ▇. ▇▇▇▇▇▇▇▇
		▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Ph.D. President and CEO						▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, III, M.D. Executive Vice President of Medical Affairs

 

		▇▇▇▇▇▇-▇▇▇▇ PHARMACEUTICALS, INC.
By:		/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
		▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇ President

 

Page 2